Senescence induction in human fibroblasts and hematopoietic progenitors by leukemogenic fusion proteins

Howard Hughes Medical Institute and Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01606, USA.
Blood (Impact Factor: 10.45). 06/2010; 115(24):5057-60. DOI: 10.1182/blood-2009-09-245928
Source: PubMed


Hematologic malignancies are typically associated with leukemogenic fusion proteins, which are required to maintain the oncogenic state. Previous studies have shown that certain oncogenes that promote solid tumors, such as RAS and BRAF, can induce senescence in primary cells, which is thought to provide a barrier to tumorigenesis. In these cases, the activated oncogene elicits a DNA damage response (DDR), which is essential for the senescence program. Here we show that 3 leukemogenic fusion proteins, BCR-ABL, CBFB-MYH11, and RUNX1-ETO, can induce senescence in primary fibroblasts and hematopoietic progenitors. Unexpectedly, we find that senescence induction by BCR-ABL and CBFB-MYH11 occurs through a DDR-independent pathway, whereas RUNX1-ETO induces senescence in a DDR-dependent manner. All 3 fusion proteins activate the p38 MAPK pathway, which is required for senescence induction. Our results reveal diverse pathways for oncogene-induced senescence and further suggest that leukemias harbor genetic or epigenetic alterations that inactivate senescence induction genes.

Download full-text


Available from: Narendra Wajapeyee, Aug 27, 2015
  • Source
    • "Although the activation of DDR by oncogene-induced hyper-replication has been shown by some groups as the key mediator of oncogene-induced senescence,31,32 other reports underline the independency of DDR in terms of senescence induction by some leukemogenic fusion proteins, such as BCR-ABL and CBFB-MYH11.33 Here, p38 kinase pathway followed by p16 induction plays a crucial role in the commitment to senescence. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cellular senescence was historically discovered as a form of cellular ageing of in vitro cultured cells. It has been under the spotlight following the evidence of oncogene-induced senescence in vivo and its role as a potent tumour suppressor mechanism. Presently, a PubMed search using keywords 'cellular senescence and cancer' reveals 8398 number of references (by April 2011) showing that while our knowledge of senescence keeps expanding, the complexity of the phenomenon keeps us - researchers in the field of cancer biology--fascinated and busy. In this short review, we summarise the many cellular pathways leading to cellular senescence and we discuss the latest experimental evidence and the questions emerging in the field.
    Full-text · Article · May 2011 · European journal of cancer (Oxford, England: 1990)
  • [Show abstract] [Hide abstract]
    ABSTRACT: Because of the statistical nature nature of many types of clutter, a radar target detector must set a fairly high threshold in order to order to maintain a reasonable false-alarm rate. However, weak targets are usually missed for the above threshold detector. This paper presents an effective detector, which can be considered as a two-dimensional feature matching filter for radar signals. The feature extraction is performed by Hopfield neural networks and the feature integration is finished by a multilayer perceptron. In order to overcome the local optimum problem, a novel modification which is called energy comparing method is introduced into the Hopfield model dynamic equation to find the global optimum. By testing with the real radar return data in a low signal-to-clutter ratio, the detector presented in this paper has more advantages than the conventional threshold detector
    No preview · Conference Paper · Jun 1994
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fanconi D2 (FANCD2) is monoubiquitinated on K561 (FANCD2-Ub) in response to DNA double-strand breaks (DSBs) to stimulate repair of these potentially lethal DNA lesions. FANCD2-Ub was upregulated in CD34+ chronic myeloid leukemia (CML) cells and in BCR-ABL1 kinase-positive cell lines in response to elevated levels of reactive oxygen species (ROS) and DNA cross-linking agent mitomycin C. Downregulation of FANCD2 and inhibition of FANCD2-Ub reduced the clonogenic potential of CD34+ CML cells and delayed BCR-ABL1 leukemogenesis in mice. Retarded proliferation of BCR-ABL1 positive FANCD2-/- leukemia cells could be rescued by FANCD2 expression. BCR-ABL1 positive FANCD2-/- cells accumulated more ROS-induced DSBs in comparison with BCR-ABL1 positive FANCD2+/+ cells. Antioxidants diminished the number of DSBs and enhanced proliferation of BCR-ABL1 positive FANCD2-/- cells. Expression of wild-type FANCD2 and FANCD2(S222A) phosphorylation-defective mutant (deficient in stimulation of intra-S phase checkpoint, but proficient in DSB repair), but not FANCD2(K561R) monoubiquitination-defective mutant (proficient in stimulation of intra-S phase checkpoint, but deficient in DSB repair) reduced the number of DSBs and facilitated proliferation of BCR-ABL1 positive FANCD2-/- cells. We hypothesize that FANCD2-Ub has an important role in BCR-ABL1 leukemogenesis because of its ability to facilitate the repair of numerous ROS-induced DSBs.
    Full-text · Article · Apr 2011 · Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Show more